Digital Health Funding Stays Robust as AI Infrastructure Plays Dominate October Rounds

Nine deals closed across digital health in the past month, and the pattern is unmistakable. Capital is concentrating in companies that automate administrative friction inside existing healthcare workflows rather than those chasing entirely new clinical categories. The largest check of the period, $350 million for EliseAI, went to a company that started in apartment leasing and expanded into healthcare only four years ago. That tells you something about where investors see durable margin.

EliseAI's round, led by Andreessen Horowitz and Bessemer Venture Partners with participation from Ontario Teachers' Pension Plan, Sapphire Ventures and Navitas Capital, pushed the company to a $4 billion valuation. The numbers back the premium. EliseAI crossed $200 million in annual recurring revenue in June and has doubled revenue year-over-year for five consecutive years running. Its platform now touches one in six apartments nationally, and more than 30 million Americans have interacted with it since launch. Bessemer's Sameer Dholakia called the company's depth of operating knowledge the reason for "measurable results" and "deep customer love." The company just launched Apollo, its first agentic AI teammate capable of handling any task across the Elise platform, suggesting the next leg of growth will come from expanding task autonomy rather than new customer segments.

Where the Capital Is Actually Going

Post-acute care is quietly becoming one of the more interesting niches for AI infrastructure spend. Basalt Health raised $20 million in a Series A led by NEA, with Frist Cressey Ventures and 25m Health participating, to automate the referral and admissions process that currently chews through enormous amounts of clinician time. The scale of the inefficiency is staggering: roughly 14 million patients enter post-acute care annually, and case managers typically fax clinical packets to 6.6 facilities per placement before securing a bed. That delay and mismatch problem contributes an estimated $17 billion in avoidable readmission costs each year. Basalt's early results with Lifepoint Health are notable: median chart processing time dropped from 8.5 minutes to 1.2 minutes, and the company is expanding into 49 additional Lifepoint markets by year end. Founder Ben Hackett, who spent nearly a decade at Accolade watching administrative work pull clinicians away from patients, is betting this operational pain point scales into a broader infrastructure play covering discharge planning and payer workflows.

Pharmacy benefits is another area attracting serious late-stage capital. Rightway closed $155 million in a Series E led by Francisco Partners, with Thrive Capital and Khosla Ventures returning, to expand its AI capabilities and pharmacy benefits technology. The company now serves 45 Fortune 500 clients with a model that caps pharmacy spend and passes through 100% of rebates, including on high-cost GLP-1 categories. CEO Jordan Feldman framed the thesis plainly: embed clinicians in the workflow, use AI on the backend, and reward prescribing decisions that lower total cost. Given how much scrutiny GLP-1 spending is drawing from employers, this is a well-timed bet.

Clinical documentation continues to attract outsized capital too. Heidi, the ambient AI scribe that started in Australia, raised $340 million combined across a $100 million Series C led by Blackbird and a $240 million growth investment from General Catalyst's Customer Value Fund. Heidi now supports roughly 2.8 million patient interactions weekly across 110 languages and 190 countries, and the company is using the capital to push beyond documentation into supervised agentic action. The jump from scribing to workflow automation is the natural next move for any ambient AI vendor with this kind of usage data, and it is where the real margin expansion will likely come from.

Smaller rounds reveal where investors are placing early, more speculative bets. Outro raised $7 million in pre-seed and seed funding from Listen Ventures, Cake Ventures, Jason Calacanis's LAUNCH and others to build out deprescribing support for antidepressants, an area HHS and CMS have both flagged this year as a policy priority. Blair Health closed CAD $4.24 million in pre-seed funding to let generalist clinicians deliver specialty-level care through encoded assessment logic. Penelope Health landed a $100 million commitment alongside a partnership with Thoreau to expand payer policy intelligence covering more than 200 million Americans. Epsilon Health emerged from stealth with $27.6 million from AlleyCorp and others to accelerate AI-assisted radiology interpretation, reportedly processing thousands of studies daily for major imaging providers within ten months of founding. Viv, a period care brand, raised a modest $2 million to fund a Whole Foods rollout of toxin-free tampons, bringing its total raised to $3.3 million. Verily also disclosed fresh, undisclosed-amount investment from NVIDIA and CU Healthcare Innovation Fund to extend its March round and scale its Verily Pre Platform.

The Bottom Line

The common thread across nearly every round this period is workflow automation layered onto AI, not novel drug discovery or diagnostics breakthroughs. Investors are paying premiums for proven usage metrics: EliseAI's doubling revenue, Basalt's processing time reductions, Heidi's weekly interaction volume. That is a rational allocation pattern given how much of healthcare's cost structure sits in administrative overhead rather than clinical innovation itself. The risk for these companies is execution against regulatory and reimbursement complexity that has defeated prior waves of health tech startups. Watch whether Rightway's rebate-pass-through model survives payer pushback, and whether Basalt's post-acute automation holds up once it scales past a single anchor client like Lifepoint. The capital is flowing freely right now, but the harder test comes when these platforms need to prove margin durability at scale, not just pilot-stage efficiency gains.